Pfizer and Roivant Sciences unveiled a new company called Priovant Therapeutics to develop and market new therapies for a wide range of autoimmune diseases with high mortality and morbidity rates.
Priovant was initiated in September 2021 when Pfizer partnered with Roivant. The agreement involved Pfizer licensing global development rights and U.S. and Japan commercial rights for the oral and topical version of brepocitinib to Priovant. Brepocitinib is a TYK2 and JAK1 dual inhibitor that has demonstrated strong efficacy rates against many highly inflammatory autoimmune disorders compared to therapies that inhibit just TYK2 or JAK1 alone.
Priovant, which is 25% owned by Pfizer, is expanding brepocitinib’s oral version as a franchise across various orphan and specialty disorders. The drug is currently being studied in two registrational programs, including a global Phase IIB study in systemic lupus erythematosus (SLE) which is expected to be fully enrolled by the second half of 2023.
Oral brepocitinib has also been studied in 14 Phase I and Phase II trials for various possible indications, such as plaque psoriasis, psoriatic arthritis, alopecia areata, ulcerative colitis and hidradenitis suppurativa.
Read more here